Clinical Trials Logo

Filter by:
NCT ID: NCT03835988 Withdrawn - Clinical trials for Osteo Arthritis Knee

Geniculate Artery Embolization for Knee Osteoarthritis

GAEKO
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

A prospective cohort study to study the effectiveness and safety profile of geniculate artery embolization for the treatment of symptomatic knee osteoarthritis.

NCT ID: NCT03831425 Withdrawn - Clinical trials for Prader-Willi Syndrome

Mitochondrial Complex I Dysfunction in PWS

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Prader-Willi Syndrome (PWS) is characterized by profound infantile hypotonia, growth delay, cognitive impairment, muscle weakness and exercise intolerance. Studies have suggested that a defect in energy metabolism, yet to be clarified, may be involved in its pathogenesis. Many PWS patients have received Coenzyme Q10, but the rationale for this and objective impact on cellular metabolism has not been clarified.

NCT ID: NCT03808506 Withdrawn - Ulcerative Colitis Clinical Trials

Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis

Start date: September 1, 2019
Phase:
Study type: Observational

Ulcerative colitis (UC) is a chronic inflammatory bowel disease which often follows a relapsing/remitting course. Anti-TNF therapies are proven to be effective in UC and studies indicate that having adequate drug levels correlate with improved patient outcomes. It is unknown, however, if a high burden of disease at baseline impacts drug utilization or loss. In this study, we investigate whether measures of high burden of disease (fecal calprotectin, bowel ultrasound, and colonoscopy) at baseline predicts low drug levels after standard anti-TNF induction therapy.

NCT ID: NCT03801889 Withdrawn - Iron Overload Clinical Trials

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

NCT ID: NCT03785184 Withdrawn - Multiple Myeloma Clinical Trials

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM). This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.

NCT ID: NCT03781622 Withdrawn - Clinical trials for Acute Ischemic Stroke

WOLF - Feasibility Neurothrombectomy Study in Acute Ischemic Stroke Patients

WOLF
Start date: June 13, 2019
Phase: N/A
Study type: Interventional

This study is being conducted as a feasibility clinical investigation to collect safety and technical performance data of the WOLF Thrombectomy Device for the removal of thrombus in the neurovasculature.

NCT ID: NCT03772288 Withdrawn - Clinical trials for Lymphoma, Non-Hodgkin

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Start date: April 3, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for TAK-659 when administered in combination with NKTR-214.

NCT ID: NCT03708913 Withdrawn - Metabolic Syndrome Clinical Trials

Neuromodulation for Hypothalamic Obesity

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The balance between hunger and satiety is imperative for an individual's survival and overall health.). Without this balance, individuals can become morbidly obese or lack adequate nutrition for survival. Craniopharyngioma (CP) is a benign tumour that occurs at the base of the brain in children. Unfortunately, pediatric neurosurgeons sometimes inadvertently destroy a child's satiety centre during CP tumour removal surgery. This leaves the child with a post-operative complication: an insatiable appetite. This form of obesity is called "hypothalamic obesity". This study is designed to investigate Deep Brain Stimulation for hypothalamic obesity in n=6 young adults who have stabilized tumours.

NCT ID: NCT03704077 Withdrawn - Gastric Cancer Clinical Trials

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

NCT ID: NCT03690245 Withdrawn - Clinical trials for Congenital Heart Defect

Initiation of Resuscitation While Attached to the Cord With Congenital Heart Disease

INSPIRE-CHD
Start date: December 18, 2018
Phase: N/A
Study type: Interventional

Before birth, the placenta (a structure with many blood vessels attached to the inside of your womb) and the umbilical cord (the umbilical cord is attached to the placenta) are sending oxygen and nutrients from the mother's blood through the umbilical cord to the baby. After a baby is born the cord is clamped and babies have to start breathing and support themselves. At the moment when a baby with congenital heart disease is born they will have their cord clamped immediately (this is called immediate cord clamping (ICC)). After ICC the clinical team will start to help a baby transition by carefully monitoring their oxygen saturation (give oxygen if needed), provide warmth, and dry and stimulate. Several animal studies have shown that clamping the cord right after birth might causes the baby to miss the benefits of receiving blood from the umbilical cord / placenta. Delayed Cord Clamping (DCC) is when the baby stays attached to the cord for a longer time. Studies show that DCC has many benefits especially for a newborn baby, such as higher iron storage, less need for blood transfusions, and improved circulation. This can be done while the baby is breathing on its own or while we help you baby breath (this is called resuscitation). This study aims to examine whether DCC while providing resuscitation in infants with CHD is helpful compared to immediate cord clamping. Prior to the birth of your baby, a sealed envelope will be opened and your baby will be randomly assigned to either the DCC with resuscitation group or the ICC group. 40 babies will be enrolled into this study, 20 in each group. In the DCC group, the umbilical cord will be clamped after 120 seconds during which time your baby will receive the care he/she requires by the NICU team. In the ICC group, the umbilical cord will be clamped immediately and he/she will be brought over the resuscitation bed to be cared for by the same team.